Pfizer's New Structure: Has The Company Learned From Past Merger Mistakes? [View article]
You are Right...
On Apr 10 01:55 AM EGGBEATER wrote:
> WE DON'T KNOW FOR SURE AS YET IF THE PFIZER/WYETH MERGER WILL TURN > OUT TO BE A SUCCESS OR A FAILURE. IT'S TOO EARLY TO TELL.- > PFIZER'S ACQUISITION OF WARNER-LAMBERT BECAME A SUCCESS THANKS TO > THE W-L BLOCKBUSTER DRUG LIPITOR, WITH SALES OF $ 12+ BILLION LAST > YEAR.- > PFIZER'S ACQUISITION OF PHARMACIA BECAME SOUR DUE TO THE SUBSEQUENT > FAILURE OF PHARMACIA'S 2 BLOCKBUSTER DRUGS CELEBREX AND BEXTRA THAT > HAD TO BE, OR WILL BE, DISCONTINUED.- > > A PHARMA COMPANY WILL EVENTUALLY HAVE TO DOWNSIZE (OR PERHAPS EVEN > DISAPPEAR) IF: 1) IT HAS NO SIGNIFICANT/PROMISING NEW COMPOUNDS IN > ITS R&D PIPELINE, AND, 2) ITS BESTSELLING PRODUCTS GO OFF PATENT > PROTECTION, WHICH IMMEDIATELY BRINGS IN THE GENERIC WOLVES WHO HAVE > BEEN WAITING TO FLOOD THE MARKET WITH SIMILAR PRODUCTS AT A FRACTION > OF THE ORIGINAL PRICE. > CAVEAT: GENERICS NOT ALWAYS PROVIDE THE SAME STANDARD QUALITY AS > THE ORIGINALLY PATENTED PRODUCT.
Is the Winner Pfizer, Merck or Roche? [View article]
The Article is a "Trash - self serving personal openion - except @PFE which is known to many of us-other than those PFE-PUMPERS at CNBC..
On Mar 21 07:04 AM donzelion wrote:
> "Roche is getting the most “bang for the buck”..." > > Why? Roche already owned 56% of Genentech. Normally, majority ownership > is not "meaningless" - far from it. Normally, the way to measure > the extra value added by buying out the extra 44% would involve serious > cost savings or synergies - but both companies, by most reports, > are well-run shops that didn't go into excessive bloat. So what's > the big advantage of merging operations and taking 100%?
Pfizer's New Structure: Has The Company Learned From Past Merger Mistakes? [View article]
On Apr 10 01:55 AM EGGBEATER wrote:
> WE DON'T KNOW FOR SURE AS YET IF THE PFIZER/WYETH MERGER WILL TURN
> OUT TO BE A SUCCESS OR A FAILURE. IT'S TOO EARLY TO TELL.-
> PFIZER'S ACQUISITION OF WARNER-LAMBERT BECAME A SUCCESS THANKS TO
> THE W-L BLOCKBUSTER DRUG LIPITOR, WITH SALES OF $ 12+ BILLION LAST
> YEAR.-
> PFIZER'S ACQUISITION OF PHARMACIA BECAME SOUR DUE TO THE SUBSEQUENT
> FAILURE OF PHARMACIA'S 2 BLOCKBUSTER DRUGS CELEBREX AND BEXTRA THAT
> HAD TO BE, OR WILL BE, DISCONTINUED.-
>
> A PHARMA COMPANY WILL EVENTUALLY HAVE TO DOWNSIZE (OR PERHAPS EVEN
> DISAPPEAR) IF: 1) IT HAS NO SIGNIFICANT/PROMISING NEW COMPOUNDS IN
> ITS R&D PIPELINE, AND, 2) ITS BESTSELLING PRODUCTS GO OFF PATENT
> PROTECTION, WHICH IMMEDIATELY BRINGS IN THE GENERIC WOLVES WHO HAVE
> BEEN WAITING TO FLOOD THE MARKET WITH SIMILAR PRODUCTS AT A FRACTION
> OF THE ORIGINAL PRICE.
> CAVEAT: GENERICS NOT ALWAYS PROVIDE THE SAME STANDARD QUALITY AS
> THE ORIGINALLY PATENTED PRODUCT.
Pfizer's New Structure: Has The Company Learned From Past Merger Mistakes? [View article]
On Apr 09 11:09 PM a. palmer jr. wrote:
> I hope this new structure will translate into higher stock prices
> for PFE so that eventually I can sell.
Is the Winner Pfizer, Merck or Roche? [View article]
On Mar 21 07:04 AM donzelion wrote:
> "Roche is getting the most “bang for the buck”..."
>
> Why? Roche already owned 56% of Genentech. Normally, majority ownership
> is not "meaningless" - far from it. Normally, the way to measure
> the extra value added by buying out the extra 44% would involve serious
> cost savings or synergies - but both companies, by most reports,
> are well-run shops that didn't go into excessive bloat. So what's
> the big advantage of merging operations and taking 100%?